- Home
- LESL vs CRGX Comparison
LESL vs CRGX Comparison
Compare LESL & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- CRGX
- Stock Information
- Founded
- LESL 1963
- CRGX 2021
- Country
- LESL United States
- CRGX United States
- Employees
- LESL N/A
- CRGX N/A
- Industry
- LESL Diversified Commercial Services
- CRGX
- Sector
- LESL Miscellaneous
- CRGX
- Exchange
- LESL Nasdaq
- CRGX Nasdaq
- Market Cap
- LESL 538.1M
- CRGX 628.6M
- IPO Year
- LESL 2020
- CRGX 2023
- Fundamental
- Price
- LESL $1.42
- CRGX $3.77
- Analyst Decision
- LESL Hold
- CRGX Hold
- Analyst Count
- LESL 10
- CRGX 7
- Target Price
- LESL $2.83
- CRGX $4.67
- AVG Volume (30 Days)
- LESL 7.3M
- CRGX 2.2M
- Earning Date
- LESL 02-06-2025
- CRGX 03-20-2025
- Dividend Yield
- LESL N/A
- CRGX N/A
- EPS Growth
- LESL N/A
- CRGX N/A
- EPS
- LESL N/A
- CRGX N/A
- Revenue
- LESL $1,331,389,000.00
- CRGX N/A
- Revenue This Year
- LESL $4.80
- CRGX N/A
- Revenue Next Year
- LESL $3.73
- CRGX N/A
- P/E Ratio
- LESL N/A
- CRGX N/A
- Revenue Growth
- LESL N/A
- CRGX N/A
- 52 Week Low
- LESL $1.40
- CRGX $3.00
- 52 Week High
- LESL $8.05
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- LESL 30.34
- CRGX 24.94
- Support Level
- LESL $1.40
- CRGX $3.27
- Resistance Level
- LESL $1.59
- CRGX $3.95
- Average True Range (ATR)
- LESL 0.15
- CRGX 0.26
- MACD
- LESL -0.04
- CRGX 0.24
- Stochastic Oscillator
- LESL 2.17
- CRGX 73.53
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.